Aa
A
A
Close
Avatar universal
Treatment of nonalcoholic steatohepatitis with probiotics
Background and aims: Gut microbiota is involved in energy harvesting and systemic inflammation. Probiotics ameliorate nonalcoholic steatohepatitis (NASH) in animal studies. We aimed to test the efficacy of probiotics treatment and study the gut microbiota composition of humans with NASH.

Methods: Patients with biopsy-confirmed NASH were randomized to receive probiotics (including 4 Lactobacillus strains and Bifidobacterium bifidum; 10 subjects) or usual care (10 subjects) for 6 months. The primary endpoint was change in hepatic triglyceride content as measured by proton-magnetic resonance spectroscopy. Gut microbiota of NASH subjects was compared to control subjects matched for age, gender and body mass index, and was assessed serially during treatment. Analysis was performed by pyrosequencing of 16S rRNA genes from fresh morning stool samples (454 Life Sciences, Branford, CT).

Results: Hepatic triglyceride content decreased by a median of 7.6% (IQR -11.5%, -0.2%) in the probiotics group (P=0.028) and increased by 0.9% (IQR -4.2%, 2.4%) in the usual care group (P=0.80). The probiotics group tended to have greater reductions in serum alanine aminotransferase (-20 IU/l vs. 10 IU/l; P=0.44), aspartate aminotransferase (-7 IU/l vs. 11 IU/l; P=0.11) and gamma-glutamyl transpeptidase (-6 IU/l vs. 14 IU/l; P=0.28) than the usual care group. The change in body mass index and other metabolic parameters did not differ between the two groups. Analysis of 8 NASH subjects and 6 controls yielded 1,287,850 partial bacterial 16S rRNA sequences. Compared to controls, NASH subjects had higher relative abundance of Bacteroides (87.8% vs. 80.8%), but lower abundance of Firmicutes (10.3% vs. 13.5%) and Fusobacterium (0.27% vs. 3.9%) (all P<10-6). Probiotics reduced the abundance of Bacteroides (92.1% to 89.1%; P<10-6) and increased the abundance of Firmicutes (6.6% to 9.4%; P<10-6), but the change was not observed in the usual care group.

Conclusions: Probiotics treatment reduces hepatic triglyceride content in patients with NASH. Altered gut microbiota is associated with NASH, and may be modified by probiotics. Our results support further evaluation of probiotics as a treatment for NASH in larger clinical trials. (ClinicalTrials.gov number, NCT00870012)
Cancel
0 Answers
Page 1 of 1
Your Answer
Avatar universal
Answer
Know how to answer? Tap here to leave your answer...
Answer
Submit Answer
A
A
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis B Community Resources
RSS Expert Activity
233488 tn?1310696703
Blank
Marathon Running Done Over Many Yea...
05/15 by John C Hagan III, MD, FACS, FAAOBlank
233488 tn?1310696703
Blank
New Article on Multifocal IOL vs &q...
05/15 by John C Hagan III, MD, FACS, FAAOBlank
748543 tn?1463449675
Blank
TMJ/TMJ The Connection Between Teet...
01/15 by Hamidreza Nassery , DMD, FICOI, FAGD, FICCMOBlank
Top Hepatitis Answerers